Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 18, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital movements.
- Shares Purchased: 250,000 ordinary shares.
- Purchase Price: 1,461.64 pence per share.
- Treasury Shares Held: 295,197,678 shares (representing 4.90% of total voting rights).
- Shares in Issue: 5,724,716,424 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the increase in the company's Treasury share holdings following the repurchase of 250,000 shares on May 18, 2007. The total number of shares in issue remains 5,724,716,424, which serves as the denominator for shareholder notification calculations under the Financial Services Authority's Disclosure and Transparency Rules.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Points
- Verify the total number of shares in issue (5,724,716,424) for compliance with disclosure thresholds.
- Confirm the updated Treasury share count (295,197,678) and its percentage of voting rights (4.90%).
- Note that this filing does not contain financial results; refer to Form 20-F for comprehensive financial data.